Member Info for sasa43

Hi Ghia - well, you've clearly got a good grasp of what's involved re: an urgent cash raise - I chuckled to myself about your last comment re: the analogy of asking a 'pack of hyenas to share their kill' vis a vis the most appealing / profitable deals on offer! - sasa.

Ghia - couldn't have answered dactions's comments any better than you've just done.
Was in the mkts for 43 years before I retired and you're right about the 'old boys club' attitude to the most lucrative cash raisings, in lieu of long winded rights issues, etc., - sasa.

Yep, it's paid tomorrow - sasa.

Echo that post, Anders - sasa.

So allow for that 42c (33p odd) downward adjustment in the sp - it's paid on the 29th May - sasa.

Hi Nolupus - didn't SNG recently do just that? They raised some £14m from a rapid book build (overnight, in fact, if I recall) to facilitate funding their on going drug trial programme(s) - okay, the offer of further shs wasn't applicable to all investors like us as it would have taken too long / been more expensive to administer when SNG's time is fully occupied on getting approval for their product but the principle's the same. They got the money they needed there and then and the Instos got their additional shs in exchange and some of these are now being bought by others.

Ergo, a stock exchange serving a distinct function...

I'm no 'green' or 'ethical investor', per se but in this case I'm very comfortable in supporting the likes of SNG and NCYT in their laudable endeavours and if they succeed and us investors make a profit in backing them, then that's our reward, too, in my book - a 'win / win' for all concerned.

Anyway, GL with your investments here and elsewhere - sasa.

Re: 'Buying shs / saving lives'; It's called 'funding,' Nolupus - if the providers of seed capital to get an enterprise off the ground have little or no chance of ultimately retrieving their money by selling their shs on to later investors, you wouldn't have a mkt in them and the state / tax payers would have to step in and provide the capital. It's called capitalism - sasa.

Echo that, Woodstock - there's an old mkt saying that 'the short term trader is a long term loser' and this seems particularly apt with 'hot' stocks like this / NCYT etc., right now.

Both seem well positioned in this crucial development area, so let them do their level best in succeeding in alleviating the pain inflicted by this evil virus and thereby benefitting the LTH's who back them with their hard earned... sasa.

And it's well covered, too, chinch (8 x eps) so it must be more reliable than other declared payers.

If SQZ was already on the main mkt, this aspect would be even more appealing to investors / Instos - it is Serica's 'aspiration' to move up there at some point - sasa.

Quite so, Dunnett - the Y/E figs are historic - the forecasts for this transformed company are the most important thing and the mkt is always forward looking.

Given what we already know / the leading 'gold standard' test provider we have here with such persistent demand for the product should more than underwrite the present sp level and see a justifiable higher rating, quite apart from any other 'developments', imv. A good stock to hold onto in these highly volatile mkt conditions - sasa.

Thanks Jack / NewK - it must be my end then...

I also use the Shares site which, for me anyway, seems more reliable but it doesn't offer L2, unfortunately, nor decent 'chat' pages, unlike this one but if LSE is so erratic (in my case) it's pretty useless.

The LSE pages seem to free up after the mkt close but by then L2 is closed, of course; thanks, anyway - sasa.

Or is it me? I'm finding it very slow and often pages 'frozen' for a while which is very irritating.

Meanwhile, it's nice to see SQZ into three figures once more - just! - sasa.

Or put another way, OLS7 - just go away with your childish attention seeking drivel - you're as much use on here as an ashtray on a motor bike! - sasa.

Agreed, NewK - these journalists never seem to properly investigate matters; sloppy reporting can unwittingly mislead readers. Quoting his decom costs 'negative' runs counter to his 'happy to buy this one' in this troubled sector.

Just a reasonable look thru' the latest RNS you've quoted would have put him right on this important aspect, as you say - sasa.

Thanks for posting those articles, SGD27 - well worth reading for those unfamiliar with their role. In essence, the MM's aren't perfect, agreed but without them, we wouldn't have a mkt at all. You'd have to get listed on the 'pink sheets' (as in the US) if you wanted to deal, not unlike trying to deal in the shs of a private company, waiting for a buyer or seller to come forward at some point and accommodate you.

For the Pi over here, the system is a helluva sight better than it used to be and the day traders back then had little or no chance! Just sayin' - sasa.

Agree Henners - sasa.

HARA - you've been given a few acronyms to help - suggest you Google others you're not sure about but above all, 'do your own research' (DYOR).

Investing is a serious business, especially on AIM, which is lightly regulated (much less than the main mkt) so be careful and only risk what you can afford to lose, bearing in mind that there are more gamblers / day traders in the junior mkt (AIM) especially where 'hot' stocks are concerned like this one - hence the additional volatility. Be careful - sasa.

Pharma - methinks that you should have waited until the trial outcome was confirmed by an RNS / the consequences for the sp going forward would be much easier to read then - unless, of course, you didn't want to miss out on any serious upside beforehand.

You may well be a medical professional but the stock mkt is quite different and I'd suggest that you've hardly got going in trying to understand how this, non - scientific, system works. Been in this game for some 60 years now and still learning how best to equate the juxtaposition of the fundamentals / potential with human behaviour (sentiment) - ATB anyway to all holders, inc. me ! - sasa.

Need to trawl through the statement again - although the eps outcome was lower than I'd expected (incidental, really) the conservative approach runs through their report which, given the current uncertainties, is clearly reassuring for all the shareholders.

In the circumstances, it was commendable of the BoD to 'honour' their earlier expectations to pay the maiden divd, instead of deferring it as many Cos have done recently and the 'half way' house of announcing 3p ps now, must surely be appreciated by all holders. Being 8 x covered by the eps just reported exemplifies the conservative approach once more and leaves ample room for maintaining distributions henceforth which they also indicated previously so, again, 'hats off' to our management on this score, as well.

Hopefully, the BoD will continue to successfully steer Serica through the present virus driven anxieties, whilst the appointment to the board of an experienced M&A NED bodes well for the acquisition possibilities (both offensive and defensive) - another plus, certainly...

Ergo, selling on a current p/e of 4 x and now yielding some 3% , the shs remain significantly under valued, amongst its peers and deserve to be accorded a decent premium to them, imv, as suggested previously. Meanwhile, much to look forward to... sasa.

Cheers, chinch / Almsivi - just noticed that announcement - sasa.